Connection

THOMAS MONATH to Male

This is a "connection" page, showing publications THOMAS MONATH has written about Male.
Connection Strength

0.361
  1. rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
    View in: PubMed
    Score: 0.040
  2. Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
    View in: PubMed
    Score: 0.016
  3. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
    View in: PubMed
    Score: 0.015
  4. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010 May; 82(5):919-21.
    View in: PubMed
    Score: 0.014
  5. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
    View in: PubMed
    Score: 0.014
  6. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009 Mar 04; 27(10):1637-44.
    View in: PubMed
    Score: 0.013
  7. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine. 2009 Mar 04; 27(10):1645-50.
    View in: PubMed
    Score: 0.013
  8. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine. 2008 Jan 24; 26(4):581-8.
    View in: PubMed
    Score: 0.012
  9. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
    View in: PubMed
    Score: 0.011
  10. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.011
  11. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005 May 09; 23(25):3301-9.
    View in: PubMed
    Score: 0.010
  12. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
    View in: PubMed
    Score: 0.010
  13. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004 Sep; 53(9):1235-43.
    View in: PubMed
    Score: 0.010
  14. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
    View in: PubMed
    Score: 0.010
  15. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
    View in: PubMed
    Score: 0.009
  16. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
    View in: PubMed
    Score: 0.009
  17. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
    View in: PubMed
    Score: 0.008
  18. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002 Jun 20; 298(1):146-59.
    View in: PubMed
    Score: 0.008
  19. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.008
  20. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
    View in: PubMed
    Score: 0.008
  21. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg Microbes Infect. 2021 Dec; 10(1):651-663.
    View in: PubMed
    Score: 0.008
  22. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001 Feb; 69(2):988-95.
    View in: PubMed
    Score: 0.007
  23. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
    View in: PubMed
    Score: 0.007
  24. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 07; 18(7):738-748.
    View in: PubMed
    Score: 0.006
  25. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017 10 12; 377(15):1438-1447.
    View in: PubMed
    Score: 0.006
  26. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
    View in: PubMed
    Score: 0.006
  27. Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
    View in: PubMed
    Score: 0.006
  28. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
    View in: PubMed
    Score: 0.005
  29. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
    View in: PubMed
    Score: 0.004
  30. Imported Lassa fever--reexamining the algorithms. N Engl J Med. 1990 Oct 18; 323(16):1139-41.
    View in: PubMed
    Score: 0.004
  31. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
    View in: PubMed
    Score: 0.003
  32. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am J Trop Med Hyg. 1989 Jun; 40(6):663-8.
    View in: PubMed
    Score: 0.003
  33. Epizootic vesicular stomatitis in Colorado, 1982: some observations on the possible role of wildlife populations in an enzootic maintenance cycle. J Wildl Dis. 1987 Apr; 23(2):192-8.
    View in: PubMed
    Score: 0.003
  34. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vaccin. 2005 May-Jun; 1(3):106-11.
    View in: PubMed
    Score: 0.003
  35. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005 Mar; 128(3):764-70.
    View in: PubMed
    Score: 0.002
  36. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
    View in: PubMed
    Score: 0.002
  37. High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection. Am J Gastroenterol. 2003 Nov; 98(11):2395-402.
    View in: PubMed
    Score: 0.002
  38. Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis. 2003 Nov 01; 188(9):1263-75.
    View in: PubMed
    Score: 0.002
  39. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest. 1983 Apr; 48(4):399-410.
    View in: PubMed
    Score: 0.002
  40. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002 Nov; 51(5):634-40.
    View in: PubMed
    Score: 0.002
  41. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
    View in: PubMed
    Score: 0.002
  42. St Louis encephalitis. Quantitative histologic and immunofluorescent studies. Arch Neurol. 1981 Jun; 38(6):329-34.
    View in: PubMed
    Score: 0.002
  43. Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
    View in: PubMed
    Score: 0.002
  44. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999 Apr; 116(4):804-12.
    View in: PubMed
    Score: 0.002
  45. Risk of Helicobacter pylori infection among long-term residents in developing countries. Am J Trop Med Hyg. 1999 Feb; 60(2):267-70.
    View in: PubMed
    Score: 0.002
  46. Arthropod-borne encephalitides in the Americas. Bull World Health Organ. 1979; 57(4):513-33.
    View in: PubMed
    Score: 0.002
  47. Necrotizing myocarditis in mice infected with Western equine encephalitis virus: Clinical, electrocardiographic, and histopathologic correlations. J Infect Dis. 1978 Jul; 138(1):59-66.
    View in: PubMed
    Score: 0.002
  48. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 1996 Jun; 110(6):1770-5.
    View in: PubMed
    Score: 0.001
  49. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
    View in: PubMed
    Score: 0.001
  50. Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ. 1975; 52(4-6):577-92.
    View in: PubMed
    Score: 0.001
  51. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg. 1974 Nov; 23(6):1140-9.
    View in: PubMed
    Score: 0.001
  52. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. Bull World Health Organ. 1973; 49(2):113-21.
    View in: PubMed
    Score: 0.001
  53. Studies on California encephalitis in Minnesota. Am J Epidemiol. 1970 Jul; 92(1):40-50.
    View in: PubMed
    Score: 0.001
  54. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg. 1989 May-Jun; 83(3):401-6.
    View in: PubMed
    Score: 0.001
  55. Human immunodeficiency virus infection in a rural community. J Fla Med Assoc. 1988 May; 75(5):301-4.
    View in: PubMed
    Score: 0.001
  56. Epidemic yellow fever in eastern Nigeria, 1986. Lancet. 1988 Mar 19; 1(8586):630-3.
    View in: PubMed
    Score: 0.001
  57. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am J Trop Med Hyg. 1987 Jan; 36(1):177-82.
    View in: PubMed
    Score: 0.001
  58. Arbovirus investigations in Argentina, 1977-1980. II. Arthropod collections and virus isolations from Argentine mosquitoes. Am J Trop Med Hyg. 1985 Sep; 34(5):945-55.
    View in: PubMed
    Score: 0.001
  59. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
    View in: PubMed
    Score: 0.001
  60. Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. Prog Clin Biol Res. 1983; 123:31-41.
    View in: PubMed
    Score: 0.001
  61. Identification of a new Venezuelan equine encephalitis virus from Brazil. Am J Trop Med Hyg. 1982 Nov; 31(6):1260-72.
    View in: PubMed
    Score: 0.001
  62. Human arboviral infections in the United States in 1980. J Infect Dis. 1982 Feb; 145(2):283-6.
    View in: PubMed
    Score: 0.001
  63. Arbovirus infections among laboratory personnel in Ibadan, Nigeria. Am J Trop Med Hyg. 1981 Jul; 30(4):855-61.
    View in: PubMed
    Score: 0.000
  64. [Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):31-43.
    View in: PubMed
    Score: 0.000
  65. [Yellow fever in Senegal from 1976 to 1980 (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):45-51.
    View in: PubMed
    Score: 0.000
  66. Studies of glucose metabolism in rhesus monkeys after Venezuelan equine encephalitis virus infection. J Med Virol. 1980; 6(3):227-34.
    View in: PubMed
    Score: 0.000
  67. St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases. Arch Intern Med. 1979 May; 139(5):561-6.
    View in: PubMed
    Score: 0.000
  68. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. Am J Trop Med Hyg. 1974 Nov; 23(6):1131-9.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.